New data on pharmacogenetics in development of arterial hypertension and effectiveness of amlodipine
https://doi.org/ 10.24411/2588-0527-2018-10001
Abstract
Presented a review of pharmacogenetic markers CYP3A5 and P-glycoprotein and it's role in increasing blood pressure and development of hypertension. Expression of the CYP3A5 isoform in the kidney is involved in the regulation of activity RAAS, aldosterone and sodium reabsorption. An additional value in the regulation of aldosterone activity of the genetic polymorphism of the known efflux- transporter of the P-glycoprotein is shown, which can also increase the level of blood pressure. Calcium antagonists and amlodipine are substrates for CYP3A5. Several foreign and domestic clinical research have shown the effect of the expression of the CYP3A5*1 allele and the variant 3435T allele of the ABCB1 gene in the more powerful hypotensive effect of amlodipine and development of vasodilatation side effects. With high expression of CYP3A5*1 the hypotensive effect of amlodipine is higher and accompanied by vasodilatation side effects.
References
1. Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep. 2010;12:17-25. DOI: 10.1007/s11906-009-0086-6.
2. Wang C. Genetic association studies: hypertension and beyond. Hypertension Res. 2011;34(3):294-295. D0I:10.1038/hr.2010.283
3. Kamide K, Kawano Y, Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertension Research. 2012;35(8):796-799. D0I:10.1038/hr.2012.82
4. Леонова М.В. Фармакогенетика артериальной гипертонии: особенности фармакогенетики торасемида. Фармакогенетика и Фармакогеномика. - 2016. - № 1. - С. 5-8.
5. Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenetics in the management of hypertension. JPharmacogenomics & Pharmacoproteomics. 2014;5:1-7. D0I:10.4172/2153-0645.1000126
6. Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta. 2007;381(1):26-31. D0I:10.1016/j.cca.2007.02.014
7. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol. 1996;50(1):52-59.
8. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-391. DOI: 10.1038/86882
9. Givens RC, Lin YS, Dowling ALS, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95(3):1297-1300. DOI: 10.1152/japplphysiol.00322.2003
10. Kreutz R, Zuurman M, Kain S, et al. The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics. 2005;15(12):831-837.
11. Kivisto KT, Niemi M, Schaeffeler E, et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients. Data from the DEBATE Study. Am J Pharmacogenomics. 2005;5:191-195. DOI: 10.2165/00129785-200505030-00005
12. Zhang L, Miyaki K, Wang W, Muramatsu M. CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens. 2010;24(5):345-350. DOI: 10.1038/jhh.2009.74
13. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004 Dec; 75(6):1059-1069.
14. Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res. 2011; 34:1216-1220. DOI: 10.1038/hr.2011.112
15. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992;267(34):24248-24252.
16. Parler RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. JCardiovasc Pharmacol. 2006;47(1):55-59.
17. Ernest S, Rajaraman S, Meguesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1977;77(3):284-289. DOI: 10.1159/000190289
18. Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin. 2013;65(5):445-454.
19. Zolk O, Jacobi J, Pahl A, et al. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007;17(2):137-144. DOI: 10.1097/01.fpc.0000239969.46594.d0
20. Widder JD, Guzik TJ, Mueller CF, et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27(4):762-768. DOI: 10.1161/01.ATV.0000259298.11129.a2
21. Bochud M, Bovet P, Burnier M, Eap CB. CYP3A5 and ABCB1 genes and hypertension. Pharmacogenomics. 2009;10(3):477-487. DOI: 10.2217/14622416.10.3.477
22. Zhang YP, Zuo XC, Huang ZJ, et al. CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens. 2014 Mar;28(3):145-149. DOI: 10.1038/jhh.2013.67
23. Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80(6):646-656. DOI: 10.1016/j.clpt.2006.09.009
24. Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality. 2009;21(5):485-491. DOI: 10.1002/chir.20588
25. Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. DOI: 10.1159/000258688
26. Морозова Т.Е., Ших Н.В., Сычев Д.А., и др. Значение полиморфизма генов АВСВ1 и CYP3A5 в прогнозировании эффективности и безопасности амлодипина у больных артериальной гипертензией 1-2-й степени. ConsilliumMedicum. - 2017. - Т. 19. - № 10. - С. 49-52
Review
For citations:
Leonova M.V. New data on pharmacogenetics in development of arterial hypertension and effectiveness of amlodipine. Pharmacogenetics and Pharmacogenomics. 2018;(1):4-8. (In Russ.) https://doi.org/ 10.24411/2588-0527-2018-10001
Views:
437
Email this article 
Post a Comment 